Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability

已完结 10 由 CHEN 发布于 2026/4/15 20:03:22

DOI:10.1021/acs.jmedchem.5c03368
作者：Yi Hou,?, ,?Xinqing Zheng,?, ,?Yiwen Zhang,?, ,?Hao Shen,?, ,?Chenxun Kang,?, ,?Han Qin,?, ,?Shuyang Cao,?, ,?Yasheng Zhu,?, ,?Xiao Wang,?, ,?Chengliang Sun,?, ,?Jiayu Ding,?, ,?Zhongrui Shi,?, ,?Lipi
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：Although PROTAC technology has been reported for targeted PI3K degradation in cancer therapy, the rational design of isoform-selective PI3K PROTACs and their safety profiles compared to thei

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyAI-Enhanced Bionic Aquatic E-Skin Enables Precise Capture of Minimal Tactile Differences Toward Undisturbed Underwater Interaction